US FDA requests removal of suicide warnings from weight-loss drugs
CNN • • business
Key Points:
- The U.S. FDA has requested drugmakers to remove label warnings about potential suicidal thoughts linked to GLP-1 weight-loss drugs, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
- This decision follows a comprehensive FDA review that found no evidence connecting GLP-1 receptor agonists to increased risk of suicidal thoughts or behavior.
- GLP-1 receptor agonists, initially developed for type 2 diabetes, work by mimicking a gut hormone that suppresses appetite and induces fullness.
- The FDA's analysis included data from 91 placebo-controlled trials with over 107,000 patients, showing no increased risk of psychiatric side effects such as anxiety, depression, or psychosis.
- Both Eli
